# Cullinan Oncology

Cullinan Oncology is a Clinical-stage biopharmaceutical (public) based in Norwalk, United States.

## Overview

- **Organization type:** Clinical-stage biopharmaceutical (public)
- **Headquarters:** Norwalk, United States
- **Region:** North America
- **Address:** Norwalk, CT, United States
- **Founded:** 2017
- **Assets under management:** Undisclosed
- **Website:** cullinanoncology.com
- **LinkedIn:** https://www.linkedin.com/company/cullinan-oncology

## Regulatory record

- **Reports private funds:** No

## About

Cullinan Oncology was founded in 2017 by a team including Nadim Ahmed and has since established a presence in Norwalk, Connecticut with additional offices in Cambridge, Massachusetts and La Jolla, California. The firm's wealth origin is not publicly disclosed, but its structure as a publicly traded company (NASDAQ: CGEM) provides transparency through SEC filings. Cullinan's investment strategy centers on developing novel oncology therapeutics across multiple modalities, including small molecules, antibodies, and cell therapies. The firm has disclosed positions in several clinical-stage assets, including CLN-619 (a MICA/B antibody for solid tumors) and CLN-978 (a CD19-targeted T cell engager). Geographic focus is primarily the United States, with clinical trial sites extending to Europe and Asia. As of 2025, Cullinan had raised over $1B in equity and debt financing, including a $280M public offering in 2021. The firm employs approximately 100 professionals across its three offices. In April 2024, Cullinan announced a strategic collaboration with MD Anderson Cancer Center to advance its pipeline (per Cullinan Oncology, April 2024). Cullinan's structural differentiator is its hub-and-spoke model — each drug candidate is developed in a separate subsidiary company, with Cullinan providing central functions like R&D, regulatory, and finance. This structure allows the firm to spin out or partner individual programs while maintaining control over the overall portfolio, a governance design rare among biotech firms of its size.

## Sectors

- Biotech
- Oncology
- Therapeutics

## Offices

- Cambridge, MA, United States
- La Jolla, CA, United States

## People

- Nadim Ahmed — President and Chief Executive Officer
- Jeffrey Jones — Chief Medical Officer
- Jacqueline Vink — Chief Financial Officer

## Questions

### Who runs investment decisions at Cullinan Oncology?

Investment decisions are led by President and CEO Nadim Ahmed, with input from Chief Medical Officer Jeffrey Jones and Chief Financial Officer Jacqueline Vink. The board of directors, composed of industry and finance veterans, oversees strategic allocation. Specific investment committee details are not publicly disclosed.

### How does Cullinan Oncology source its drug programs?

Cullinan sources through internal discovery, academic partnerships, and in-licensing. The hub-and-spoke model allows each subsidiary to pursue independent research while leveraging central resources. Notable collaborations include a 2024 partnership with MD Anderson Cancer Center.

### Does Cullinan Oncology do direct investments or fund-of-funds?

Cullinan Oncology does not invest in external funds or make financial investments. It deploys capital directly into its own drug development programs. The firm's model is entirely direct — developing assets within its subsidiaries.

### What investment stages does Cullinan Oncology typically target?

Cullinan focuses on preclinical through Phase II clinical stages, targeting novel oncology targets. The firm has advanced assets from discovery into clinical trials, with one program (CLN-619) in Phase I. It does not target approved drugs or late-stage commercialization.

### Which sectors does Cullinan Oncology explicitly avoid?

Cullinan Oncology explicitly avoids non-oncology therapeutic areas and drug modalities outside small molecules, antibodies, and cell therapies. The firm does not invest in medical devices, diagnostics, or digital health. Its entire pipeline is focused on oncology.

## Related profiles

- [Jokake Companies](https://altss.com/profile/jokake-companies)
- [Aditim](https://altss.com/profile/aditim)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/cullinan-oncology

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology